Viewing Study NCT01188109



Ignite Creation Date: 2024-05-05 @ 10:46 PM
Last Modification Date: 2024-10-26 @ 10:24 AM
Study NCT ID: NCT01188109
Status: TERMINATED
Last Update Posted: 2016-09-28
First Post: 2010-07-23

Brief Title: GemcitabineCisplatin for Resected Pancreas Cancer Establishing the Role of ERCC1 in Treatment Decision
Sponsor: Emory University
Organization: Emory University

Study Overview

Official Title: GemcitabineCisplatin for Resected Pancreas Cancer Establishing the Role of Excision Repair Cross Complementation Gene 1 ERCC1 in Treatment Decision
Status: TERMINATED
Status Verified Date: 2016-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Slow accrual
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to investigate if the investigators can use a specific marker in the pancreatic tumor itself to determine which patients will benefit from receiving combination chemotherapy of gemcitabine and cisplatin after undergoing resection of a pancreatic cancer

The investigators will also investigate if there is any benefit to receiving both chemotherapy drugs as opposed to only gemcitabine after undergoing complete resection of the tumor
Detailed Description: The study will specifically be looking at ERCC1 expression in pancreas cancer with regards to its prognostic and predictive value as a biomarker for patients receiving Gem Cis as adjuvant therapy after resection

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
WCI1738-09 OTHER Other None